159 related articles for article (PubMed ID: 33962291)
1. Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Ebert M; Raquet E; Schweisgut S; Schmidt PM; Weimer T
Blood Cells Mol Dis; 2021 Jul; 89():102570. PubMed ID: 33962291
[TBL] [Abstract][Full Text] [Related]
2. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
3. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Welsch DJ; Novotny WF; Wun TC
Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
[TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
5. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
6. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutics for hemophilia and other bleeding disorders.
Callaghan MU; Sidonio R; Pipe SW
Blood; 2018 Jul; 132(1):23-30. PubMed ID: 29769259
[TBL] [Abstract][Full Text] [Related]
8. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Bauer KA; Mannucci PM; Gringeri A; Tradati F; Barzegar S; Kass BL; ten Cate H; Kestin AS; Brettler DB; Rosenberg RD
Blood; 1992 Apr; 79(8):2039-47. PubMed ID: 1562731
[TBL] [Abstract][Full Text] [Related]
9. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
11. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
12. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):605-609. PubMed ID: 29222310
[TBL] [Abstract][Full Text] [Related]
13. Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Persson E
Thromb Res; 2012 May; 129 Suppl 2():S51-3. PubMed ID: 22405049
[TBL] [Abstract][Full Text] [Related]
14. Plasma-derived factors VIIa and X mixtures (Byclot
Ochi S; Takeyama M; Shima M; Nogami K
Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
[TBL] [Abstract][Full Text] [Related]
15. Hemophilia patients: are they naturally anticoagulated?
Tripodi A; Mannucci PM; Peyvandi F
Intern Emerg Med; 2023 Aug; 18(5):1251-1254. PubMed ID: 37515677
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
18. An alternative extrinsic pathway of human blood coagulation.
Marlar RA; Kleiss AJ; Griffin JH
Blood; 1982 Dec; 60(6):1353-8. PubMed ID: 7139124
[TBL] [Abstract][Full Text] [Related]
19. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
20. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Can J Anaesth; 2002 Dec; 49(10):S7-14. PubMed ID: 12546000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
